🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for Advanced Cancer

Ph II Study of Enfortumab Vedotin in Patients With Advanced or Metastatic CRC or HCC NCT06553885Phase 21 site📍 Tampa H. Lee Moffitt Cancer Center and Research Institute · Tests: Enfortumab Vedotin Safety, Pharmacokinetics (PK), and Efficacy of ONC-783 in Advanced Solid Tumors NCT07408258Phase 13 sites📍 New York📍 Philadelphia📍 Houston OncoC4, Inc. · Tests: ONC-783 RecistTM Criteria in Evaluating the Efficacy of Targeted Therapy for NSCLC NCT06142058n/a1 site📍 Chongqing Xueqin Yang · Tests: RecistTM criteria Bolstering Outcomes After Induction With Osimertinib Plus Chemotherapy Through Optimized Site-Directed Primary Tumor Therapy (BOOST Trial) NCT07073365Phase 21 site📍 Busan Pusan National University Hospital · Tests: Local Therapy (Surgery or Radiotherapy) A Phase I First-in-Human Study of GenSci128 in Patients With Solid Tumors Harboring a TP53 Y220C Mutation NCT06908434Phase 11 site📍 Shanghai Changchun GeneScience Pharmaceutical Co., Ltd. · Tests: GenSci128 tablets SCRT VS LCRT Followed by PD-L1 Inhibitor Plus CAPEOX as TNT in Patients With LARC NCT07284992Phase 21 site📍 Jinan Shandong Provincial Hospital · Tests: short-term radiotherapy combined with Adebrelimab and capox, long-term radiotherapy combined with Adebrelimab and capox A Study of TY-2699a in Patients With Locally Advanced or Metastatic Solid Tumors NCT05866692Phase 12 sites📍 Beijing📍 Jinan TYK Medicines, Inc · Tests: TY-2699a Trilaciclib in Combination With Docetaxel for Second-Line and Beyond Treatment of Locally Advanced or Metastatic NSCLC NCT06929936Phase 21 site📍 Xiamen The First Affiliated Hospital of Xiamen University · Tests: Trilaciclib combined with Docetaxel VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma NCT03556228Phase 1, Phase 215 sites📍 Santa Rosa📍 Hartford📍 Washington D.C. VM Oncology, LLC · Tests: VMD-928 100 mg Tablet, VMD-928 Tablet and Pembrolizumab (200 mg) A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment. NCT07062965Phase 3433 sites📍 Anchorage📍 Chandler📍 Gilbert Pfizer · Tests: PF-07248144, Fulvestrant, Everolimus, Exemestane Substudy 06E: Umbrella Study of Combination Therapies in Esophageal Cancer (MK-3475-06E/KEYMAKER-U06) NCT06780111Phase 1, Phase 252 sites📍 Pittsburgh📍 Natal📍 Porto Alegre Merck Sharp & Dohme LLC · Tests: Pembrolizumab, I-DXd, Leucovorin, Levoleucovorin, 5-Fluorouracil (5-FU) Pulmonary Rehabilitation in Advanced Lung Cancer Survivors NCT07104630Phase 21 site📍 Cleveland Case Comprehensive Cancer Center · Tests: Pulmonary Rehabilitation (PR), No intervention: Usual care ChemoINTEL Assay Algorithm Development Study: In-Vitro Cytotoxic Drug Induced Apoptosis Correlation with Patient Clinical Response to Administered Chemotherapy in Patients NCT06844136n/a1 site📍 Liverpool Pierian Biosciences · Tests: No intervention A Dose Optimization/Expansion Study of SAR445877 in Adult Chinese Participants With Advanced Gastric or Gastroesophageal Junction Cancer NCT07692204Phase 21 site📍 Shanghai Sanofi · Tests: SAR445877 Study of CEA Targeting CAR-T (PTC13) in the Treatment of CEA-Positive Advanced Malignant Solid Tumors NCT06821048Phase 11 site📍 Hangzhou Weijia Fang, MD · Tests: Intraperitoneal infusion of FAST CEA-targeted CAR-T Basal-like PDAC Treated With Gemcitabine, Erlotinib, and Nab-paclitaxel NCT06483555Phase 1, Phase 21 site📍 Chapel Hill UNC Lineberger Comprehensive Cancer Center · Tests: Gemcitabine, Nab paclitaxel, Erlotinib, NALIRIFOX, Folfirinox An Phase Ib/II Clinical Trial of TCC1727 Combination Therapy in Advanced Solid Tumors NCT07371663Phase 1, Phase 23 sites📍 Beijing📍 Zhengzhou📍 Hangzhou Beijing Tide Pharmaceutical Co., Ltd · Tests: TCC1727 tablet 90mg, TCC1727 tablet 120mg, TCC1727 tablet 160mg, benmelstobart Injection Aspects of Quality of Life During Adjuvant Oncological Treatment for Locally Advanced Lung Cancer Which Include Immune Checkpoint Inhibitor. NCT07754409n/a1 site📍 Gothenburg Göteborg University TGRX-1942 Chinese Phase I for Advanced Solid Tumor And/or Relapsed/Refractory Hematologic Malignancies NCT06484816Phase 11 site📍 Hangzhou Shenzhen TargetRx Co., Ltd. · Tests: TGRX-1942 Comparing Tunlametinib Capsules and Combination Chemotherapy in Advanced NRAS-mutant Melanoma NCT06008106Phase 31 site📍 Beijing Shanghai Kechow Pharma, Inc. · Tests: tunlametinib, paclitaxel +carboplatin, or temozolomide +cisplatin, or dacarbazine +cisplatin Camrelizumab in Combination With Apatinib Mesylate Plus Short-course Chemotherapy for Advanced ESCC NCT05738434Phase 21 site📍 Zhengzhou The First Affiliated Hospital of Zhengzhou University · Tests: Camrelizumab+Apatinib+Chemotherapy→Camrelizumab+Apatinib, Camrelizumab+Chemotherapy→Camrelizumab Postoperative Radiotherapy Followed by Immunotherapy for Locally Advanced Esophageal Carcinoma NCT05937438Phase 1, Phase 21 site📍 Hefei Anhui Provincial Hospital · Tests: Immune Checkpoint Inhibitors Circulating and Urine Tumor DNA Dynamics Predict Minimal Residual Disease and Recurrence Risk in Locally Advanced Upper Tract Urothelial Carcinoma NCT05595408n/a1 site📍 Shanghai RenJi Hospital · Tests: Adjuvant chemotherapy, adjuvant immunotherapy Naltrexone and Propranolol Combined With Immunotherapy NCT05968690Phase 11 site📍 New Brunswick Sarah Weiss · Tests: Propranolol, Naltrexone A Study of MT-4561 in Patients With Various Advanced Solid Tumors NCT06943521Phase 1, Phase 26 sites📍 Los Angeles📍 Grand Rapids📍 Columbus Tanabe Pharma America, Inc. · Tests: MT-4561 A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies NCT07195916Phase 122 sites📍 Duarte📍 La Jolla📍 Ann Arbor Incyte Corporation · Tests: INCA036873 A Clinical Study of LM103 Injection in the Treatment of Advanced Solid Tumors NCT05366478Phase 11 site📍 Tianjin Suzhou BlueHorse Therapeutics Co., Ltd. · Tests: Autologous tumor infiltrating lymphocytes (TILs) Study of GS-2426 in Participants With Advanced Solid Tumors NCT07601243Phase 16 sites📍 Boston📍 Grand Rapids📍 East Brunswick Gilead Sciences · Tests: GS-2426 A Study of JNJ-87704916, as Monotherapy and in Combination for Advanced Solid Tumors NCT06311578Phase 110 sites📍 New York📍 Philadelphia📍 Pittsburgh Johnson & Johnson Enterprise Innovation Inc. · Tests: JNJ-87704916, Cetrelimab, Standard of Care PD(L)-1 Clinical Study on the First-line Treatment of Advanced Colorectal Cancer With Simultaneous Infusion of Levozolinate for Injection and 5-FU NCT07391618Phase 21 site📍 Beijing Chinese PLA General Hospital · Tests: mFOLFOX/FOLFIRI ( Standard Chemotherapy)
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy